Substance Use History and Injury Medication: Pharmacy Lien Guide

James Wong — Founder & Pharmacist, LienScripts | March 29, 2026 | 7 min read

Personal injury patients with a substance use disorder history require carefully designed non-opioid pain protocols, medication-assisted treatment continuation, and thorough prescribing documentation. A pharmacy lien ensures these patients access appropriate medications while the pharmacy record supports the attorney's case.

Personal injury patients with a history of substance use disorder require medication protocols that balance effective pain management with relapse prevention — including non-opioid analgesic strategies, medication-assisted treatment continuation, and careful prescribing documentation. A pharmacy lien ensures these patients receive appropriate, clinically supervised medications at zero upfront cost while generating a pharmacy record that demonstrates responsible, evidence-based treatment.

• Patients with SUD history require non-opioid or opioid-sparing pain protocols that are often more complex and more expensive than standard regimens
• Medication-assisted treatment (MAT) with buprenorphine or naltrexone must continue without interruption during injury recovery
• The pharmacy record documenting a deliberate, non-opioid-centric treatment plan is powerful evidence against defense claims of drug-seeking behavior
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report documenting the clinical rationale for each medication selection in the demand package

The Clinical Challenge: Pain Management Without Relapse Risk

When a personal injury patient has a documented history of opioid use disorder, alcohol use disorder, or other substance use disorder, the treating physician faces a genuine clinical dilemma. The patient has a legitimate injury requiring effective pain management, but standard opioid-based pain protocols carry elevated risk of relapse or re-initiation of problematic use patterns.

This clinical challenge does not mean the patient should receive inadequate pain treatment. Undertreated pain in patients with SUD history actually increases relapse risk — the patient may seek illicit substances to manage pain that their medical team failed to address. The answer is not less treatment but different treatment: a carefully designed multi-modal pain protocol that achieves effective analgesia through non-opioid or opioid-sparing mechanisms.

[!KEY] Undertreated pain in a patient with substance use history increases relapse risk — the clinically appropriate response is not withholding pain medication but designing a multi-modal non-opioid protocol that achieves effective analgesia while minimizing addiction triggers, and a pharmacy lien ensures this more complex regimen is accessible at zero cost.

Non-Opioid Pain Management Protocols

First-line agents:

• Gabapentin or pregabalin — neuropathic pain agents effective for both nerve injury pain and as general analgesic adjuncts, with low addiction potential
• Duloxetine (Cymbalta) — SNRI antidepressant with FDA-approved chronic pain indications, addressing both pain and the depression common in SUD patients after injury
• Celecoxib or meloxicam — COX-2 selective NSAIDs for inflammatory pain with lower GI risk than non-selective NSAIDs
• Topical agents (lidocaine patches, diclofenac gel) — localized pain relief without systemic exposure

Second-line and adjunctive agents:

• Cyclobenzaprine or tizanidine — muscle relaxants for spasm-related pain, with abuse potential lower than benzodiazepines
• Acetaminophen (scheduled dosing) — baseline analgesia without opioid or NSAID risk profiles
• Ketamine (low-dose, specialist-supervised) — NMDA receptor antagonist used for refractory pain, increasingly available in outpatient settings for patients who cannot use opioids
• Capsaicin (high-concentration topical) — for localized neuropathic pain

According to James Wong, PharmD, founder of LienScripts, "The non-opioid pain protocol for a patient with SUD history is typically more complex and involves more medications than a standard opioid-based protocol — gabapentin plus duloxetine plus topical lidocaine plus scheduled acetaminophen versus a single opioid prescription — and that complexity is itself evidence of how seriously the treating team took this patient's pain and their recovery."

[!TIP] A multi-drug non-opioid pain protocol documented in the pharmacy record is stronger evidence of legitimate injury treatment than a single opioid prescription — it demonstrates that the treating physician designed a deliberate, individualized pain management strategy rather than defaulting to the simplest prescribing option.

Medication-Assisted Treatment Continuation

Patients receiving medication-assisted treatment for opioid use disorder must continue their MAT regimen without interruption during injury recovery:

Buprenorphine (Suboxone, Sublocade): Patients on buprenorphine maintenance present unique pain management considerations. Buprenorphine is a partial opioid agonist that provides some baseline analgesia but also complicates the use of full opioid agonists for acute pain. The treating physician must coordinate pain management around the buprenorphine regimen — typically by either maintaining the buprenorphine dose and adding non-opioid adjuncts, or (in severe acute pain situations) temporarily adjusting buprenorphine under addiction medicine specialist supervision.

Naltrexone (Vivitrol): Patients on naltrexone, an opioid antagonist, cannot receive opioid analgesics while the medication is active. Pain management must rely entirely on non-opioid mechanisms. For patients on monthly Vivitrol injections, the timing of the injection relative to injury and any planned surgical procedures requires coordination.

Methadone maintenance: Patients on methadone maintenance for OUD continuation require coordination between the methadone clinic and the injury treatment team. Methadone dosing for OUD maintenance is separate from any pain management considerations.

[!KEY] Continuation of medication-assisted treatment during injury recovery is a clinical and legal necessity — interrupting buprenorphine or naltrexone to prescribe standard opioids would constitute a clinical failure that could trigger relapse, and the pharmacy record showing uninterrupted MAT alongside appropriate injury treatment documents responsible care.

Addressing Defense Attacks on SUD History

Defense counsel in PI cases involving patients with SUD history will predictably attempt to use the substance use history to undermine the plaintiff's credibility and minimize damages. The pharmacy record is the primary defense against these attacks.

The deliberate protocol argument: A pharmacy record showing gabapentin, duloxetine, topical lidocaine, and scheduled acetaminophen — with no opioids — demonstrates that the treating physician assessed the patient's history and designed a protocol specifically to manage pain without relapse risk. This is the opposite of drug-seeking behavior.

The MAT continuation argument: Uninterrupted buprenorphine or naltrexone documented in the pharmacy record shows that the patient was actively engaged in recovery throughout the PI case — evidence of responsibility, not vulnerability.

The treatment complexity argument: The non-opioid protocol is more complex, requires more medications, and demands more clinical attention than standard opioid-based treatment. This complexity supports, rather than undermines, the damages claim.

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages that articulates the clinical rationale for each medication selection in the context of the patient's SUD history.

Pharmacy Lien Access for SUD History Patients

Non-opioid pain protocols often cost more than opioid-based alternatives. Gabapentin, duloxetine, topical lidocaine patches, and other non-opioid agents can carry higher out-of-pocket costs than generic opioids. A pharmacy lien eliminates the financial pressure that might otherwise push a patient with SUD history toward cheaper but more dangerous medication options.

The pharmacy lien also provides a structured dispensing relationship: regular fills at a consistent pharmacy where the pharmacist monitors for drug interactions, adherence patterns, and any concerning changes in the medication profile.

Related Resources

• Non-Opioid Pain Management
• Pharmacy Services for Personal Injury Clients
• Buprenorphine for Chronic Pain in PI